(Q38046514)

27 August 2017

title

Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer (English)

1 reference

27 August 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

Robert S Kerbel

1

1 reference

27 August 2017

publication date

26 September 2012

1 reference

Journal of Mammary Gland Biology and Neoplasia

27 August 2017

published in

1 reference

27 August 2017

volume

17

1 reference

27 August 2017

issue

3-4

1 reference

27 August 2017

page(s)

229-239

1 reference

Tumor angiogenesis: therapeutic implications

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Avastin's uncertain future in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Avastin hearing leads to more uncertainty over drug's future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Avastin saga reveals debate over clinical trial endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Reputation and precedent in the bevacizumab decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Bevacizumab and breast cancer: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Fighting fire with fire: rekindling the bevacizumab debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Progression-free survival: meaningful or simply measurable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Antiangiogenic therapy--evolving view based on clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Combining antiangiogenics to overcome resistance: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Mouse models of advanced spontaneous metastasis for experimental therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-012-9266-0

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO

21 January 2018

1 reference

12 December 2020

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Raising the bar for cancer therapy models

1 reference

12 December 2020

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

12 December 2020

Survival is not a good outcome for randomized trials with effective subsequent therapies.

1 reference

12 December 2020

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study

1 reference

12 December 2020

Bevacizumab in ovarian cancer

1 reference

12 December 2020

Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

1 reference

12 December 2020

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

1 reference

12 December 2020

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

Bevacizumab treatment for solid tumors: boon or bust?

1 reference

12 December 2020

10.1007/S10911-012-9266-0

Identifiers

DOI

1 reference

27 August 2017

1 reference